10-Q: Journey Medical Corporation Reports Second Quarter 2024 Financial Results

Journey Medical Corporation's Q2 2024 results show a decrease in revenue and a net loss, but also a reduction in operating expenses and a new loan facility.

Summary

• Journey Medical Corporation reported a net loss of $3.4 million for the three months ended June 30, 2024, compared to a net loss of $8.4 million for the same period in 2023.
• Total revenue decreased to $14.9 million in Q2 2024 from $17.2 million in Q2 2023, primarily due to lower product sales.
• Operating expenses decreased to $17.8 million in Q2 2024 from $24.8 million in Q2 2023, driven by lower research and development and selling, general and administrative costs.
• The company's cash and cash equivalents were $23.9 million as of June 30, 2024, down from $27.4 million at the end of 2023.
• A new $20 million term loan facility was established with SWK Funding LLC, with $15 million drawn initially and an additional $5 million drawn in June 2024.
• The company issued 289,744 shares of common stock under its at-the-market offering, generating net proceeds of $1.5 million.
• The company has a shelf registration statement for up to $150 million of securities, with 3,861,553 shares remaining available for issuance as of June 30, 2024.
• The company is required to repay a portion of the outstanding principal of the term loans quarterly beginning in February 2026.
• The company has a going concern warning due to recurring losses.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive aspects such as reduced operating expenses and the FDA acceptance of the DFD-29 NDA, the decrease in revenue and the net loss, along with the going concern warning, temper the overall sentiment. The company is facing financial challenges but is taking steps to address them.

Positives

• The company's net loss decreased significantly year-over-year, indicating improved financial performance.
• Operating expenses were reduced by 28% in Q2 2024 compared to Q2 2023, showing effective cost management.
• The company successfully drew down the remaining $5 million under its credit facility, providing additional capital.
• The FDA accepted the NDA for DFD-29, a key product candidate, with a PDUFA goal date set for November 4, 2024.
• The company raised $1.5 million through the sale of common stock under its at-the-market offering.

Negatives

• Total revenue decreased by 13% in Q2 2024 compared to Q2 2023, primarily due to lower product sales.
• The company experienced a net loss of $3.4 million in Q2 2024.
• Cash and cash equivalents decreased from $27.4 million at the end of 2023 to $23.9 million as of June 30, 2024.
• The company has a going concern warning due to recurring losses.

Risks

• The company's products are subject to time and cost-intensive regulation and clinical testing, which may delay or prevent commercialization.
• A substantial portion of the company's sales come from products without patent protection, making them vulnerable to generic competition.
• The company operates in a heavily regulated industry, and future legislation could impact operations.
• The company's revenue is heavily dependent on sales of dermatology products, and any setback could impair results.
• The company faces competition from manufacturers of generic versions of its products.
• The company's products may not achieve broad market acceptance.
• The company relies on third parties for several aspects of its operations.
• The company's success depends on its ability to identify, develop, and acquire or in-license products.
• The company's business depends on the successful development and regulatory approval of DFD-29.
• Clinical drug development is expensive, time-consuming, and uncertain.
• The company's competitors could develop and commercialize similar products.
• The company faces risks related to the protection of its intellectual property.
• The company's business could suffer from computer system failures or cyber-attacks.
• Major public health issues could impact product revenues and clinical trials.
• The company may need to raise additional capital.
• Fortress Biotech controls a voting majority of the company's common stock, which could be detrimental to other shareholders.

Future Outlook

The company may seek to raise capital through debt or equity financings to expand its product portfolio and for other strategic initiatives. The company's expectations are based on current assumptions, projected commercial sales of products, clinical development plans and regulatory submission timelines, which may be uncertain and may not emerge as expected. The company is also awaiting FDA approval for DFD-29.

Management Comments

• The company is managed by experienced life science executives with a track record of creating value for their stakeholders and bringing novel medicines to the market.
• Management is focused on improving operational efficiencies, optimizing expenses and reducing overall costs.

Industry Context

The company operates in the competitive pharmaceutical industry, specifically in the dermatology sector. The company faces competition from both branded and generic drug manufacturers. The company's focus on acquiring and developing dermatology products aligns with the industry trend of companies seeking to expand their portfolios through strategic acquisitions and licensing agreements.

Comparison to Industry Standards

• Journey Medical's revenue decline of 13% in Q2 2024 is concerning, as many pharmaceutical companies aim for consistent growth. For example, companies like Galderma and Almirall, which also focus on dermatology, have shown more stable revenue trends in recent quarters.
• The company's net loss of $3.4 million, while an improvement year-over-year, still indicates financial challenges. Compared to companies like Cutera, which has shown a path to profitability, Journey Medical needs to demonstrate a clearer path to positive earnings.
• The reduction in operating expenses by 28% is a positive sign, but it needs to be balanced with revenue growth. Companies like InMode have shown that cost management can be effective when coupled with strong sales performance.
• The company's reliance on a few key products, such as Qbrexza and Accutane, makes it vulnerable to market fluctuations. Diversification of the product portfolio is crucial, similar to what companies like Bausch Health have done to mitigate risk.
• The successful NDA acceptance for DFD-29 is a significant milestone, but the company needs to ensure a smooth commercial launch, similar to how companies like AbbVie have successfully launched new products.
• The company's cash position of $23.9 million is relatively low compared to larger pharmaceutical companies, which typically have larger cash reserves to fund operations and acquisitions. Companies like Teva Pharmaceuticals have significantly larger cash reserves, providing them with more financial flexibility.

Related Party Transactions

• The company has a Shared Services Agreement with Fortress Biotech, where the company reimburses Fortress for certain employee and administrative costs.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and the net loss, as well as the going concern warning.
• Employees may be affected by the company's cost management efforts.
• Customers may be impacted by the company's product portfolio and pricing strategies.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• The company is awaiting FDA approval for DFD-29, with a PDUFA goal date of November 4, 2024.
• The company will continue to evaluate market conditions and financing alternatives to enhance its capital structure.
• The company is required to repay a portion of the outstanding principal of the term loans quarterly beginning in February 2026.

Key Dates

Keywords

dermatology, pharmaceutical, FDA, DFD-29, Qbrexza, Accutane, revenue, net loss, clinical trials, licensing, SWK Funding, at-the-market offering